A Free, Live Webinar Hosted by the Scleroderma Research Foundation on June 28, 2012
SAN FRANCISCO, June 12, 2012 /PRNewswire-USNewswire/ -- The Scleroderma Research Foundation (SRF) welcomes actor, comedian and Foundation Board Member Bob Saget to talk candidly about his involvement with scleroderma and the organization dedicated exclusively to finding a cure. The free one-hour webinar is not just for patients but also for those who may know someone with the disease or are just curious about it.
"Scleroderma" literally means "hard skin," but it often affects internal organs with life-threatening consequences. Approximately four out of five patients are women with typical onset between the ages of 20 and 50, but scleroderma also strikes men and children across all ages and ethnic boundaries.
In a live, unscripted Conversation about Scleroderma, Saget will discuss the loss of his sister to the disease, his involvement as a Board Member and advocate for patients as well as how others can raise awareness and help find a cure. The conversation will include Luke Evnin, Ph.D., Chairman of the SRF Board of Directors and a scleroderma patient, who will discuss how medical research is advancing and changing the landscape for patients. A Q&A session will follow.
Thursday, June 28, 2012 from 11:00 a.m. – 12:00 p.m. PDT. The Webinar will be available for later viewing on the SRF website.
Register online at www.sclerodermaRESEARCH.org.
About Scleroderma Research Foundation:
The Scleroderma Research Foundation is America's leading nonprofit investor in medical research aimed at improved therapies and a cure for scleroderma. It was founded in San Francisco in 1987 by patient Sharon Monsky who lost her battle to the disease in 2002. Monsky's legacy lives on through the organization, chaired by Luke Evnin, Ph.D., managing partner of MPM Capital, one of the world's largest dedicated investors in life sciences.
The Foundation's renowned Scientific Advisory Board and collaborative approach are enabling scientists from leading institutions to work together, developing an understanding of how scleroderma begins, how it progresses and what can be done to slow, halt or reverse the disease process.
SOURCE Scleroderma Research Foundation